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Parallel tales: microvascular angina and heart failure with preserved ejection fraction 
In the past decade, a growing body of studies has clearly demonstrated that coronary microvascular 
dysfunction (CMD) plays a pivotal role in several cardiovascular diseases1. In particular, emerging 
evidence suggests that CMD is the main contributor to myocardial ischemia in a large subset of 
patients with chronic stable angina. Indeed, non-obstructive coronary atherosclerosis is observed in 
up to 50% of patients with anginal symptoms and positive stress test results, undergoing diagnostic 
coronary angiography2. Thus, the prevalence of microvascular angina (MVA) is higher than 
previously thought and is associated with worse clinical outcome than that observed in 
asymptomatic subjects with a similar burden of risk factors3.  The diagnosis of MVA is based on 
the following: 1) symptoms of myocardial ischemia; 2) absence of obstructive coronary artery 
disease; 3) evidence of myocardial ischemia; 4) evidence of impaired coronary microvascular 
function. The reason why the clinical relevance of MVA has previously been overlooked is 
probably because exploration of the coronary microcirculation has been elusive to routine 
diagnostic tools until recently. A parallel “tale” could be told regarding heart failure (HF) with 
preserved ejection fraction (HFpEF). Indeed, HFpEF is observed in about 50% of patients 
presenting with HF symptoms and is characterized by the absence of the hallmark of HF, i.e. a 
reduced EF4. As with MVA, patients with HFpEF have a worse clinical outcome compared with 
asymptomatic subjects exhibiting a similar burden of risk factors. The diagnosis of HFpEF is based 
on the following: 1) typical symptoms of HF, 2) typical signs of heart failure, 3) a non-dilated left 
ventricle with normal or only mildly reduced EF, 4) relevant structural heart disease (i.e. left 
ventricular hypertrophy, left atrial enlargement) and/or diastolic dysfunction. In both MVA and 
HFpEF, no therapeutic intervention has hitherto been proven to improve patient outcome; similarly, 
symptomatic treatment is largely empirical. 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
3 
 
The common soil hypothesis 
Based on the above considerations the question arises as to whether these parallel “tales” of MVA 
and HFpEF represent two extreme clinical presentations of a disease continuum (Figure).  This 
tantalizing question is justified by the results of recent studies showing that CMD can be 
demonstrated not only in MVA but also in HFpEF5,6. The hypothesis of a common soil for these 
two conditions appears to be endorsed by the clinical observation that dyspnoea is present in a large 
proportion of patients with MVA and, vice versa, angina-like symptoms are reported in about 50% 
of those with HFpEF7. Several triggers have been identified to contribute to CMD, including 
traditional risk factors such as smoking, hypertension and diabetes as well as chronic inflammatory 
diseases, such as chronic obstructive pulmonary disease, chronic kidney disease and auto-immune 
conditions. CMD has been well documented in MVA and is responsible for the reduced coronary 
flow reserve (CFR) frequently observed in this condition.  
Recent studies suggest that CMD might play a key role also in HFpEF. Indeed, endothelial 
activation/dysfunction reduce nitric oxide (NO) bioavailability, cyclic guanosine monophosphate 
content, and protein kinase G in adjacent cardiomyocytes8. These changes are known to favour 
hypertrophy and fibrosis contributing to diastolic dysfunction. The importance of inflammation in 
the induction of cardiac fibrosis and HF has recently been convincingly demonstrated. TGF 
(transforming growth factor)- is likely to play a major role in this setting, as suggested by the 
observation that disruption of TGF-signalling attenuates pressure overload-induced interstitial 
fibrosis in the heart9. Furthermore, endothelial dysfunction contributes to cardiac fibrosis via the 
reduced bioavailability of NO, known to exert direct anti-fibrotic effects involving the cyclic 
guanosine monophosphate pathway10. Finally, NO deprivation favours endothelial cells conversion 
to a mesenchymal cell type that can gives rise to fibroblasts11. Thus, a cross-talk between the 
endothelium and the surrounding myocardium seems to play a key role in the pathogenesis of 
HFpEF.  
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Modulating factors 
A critical question is why if there is a “common soil” nurturing the development of MVA and 
HFpEF or by the same token, a continuum of disease, angina prevails at one extreme of the 
spectrum of clinical presentations (MVA) while dyspnoea prevails at the other extreme (HFpEF). A 
first response to this intriguing question comes from a large body of evidence suggesting that in 
patients with MVA two important additional alterations contributing to angina severity are: 1) 
hyper-reactivity of smooth muscle cells to constrictor stimuli in coronary microvessels; 2) enhanced 
perception of cardiac algogenic stimuli.  Indeed, a large percentage of patients with MVA develop 
coronary microvascular spasm, anginal pain and ST-segment depression following the 
intracoronary administration of acetylcholine (ACh)12. Of note, recent clinical evidence indicates 
that coronary microvascular spasm in patients with CMD can cause subtle contractile abnormalities, 
and can be associated with mild elevations of high sensitivity cTn13. Although still a working 
hypothesis at present, it is tempting to speculate that coronary “microvascular” and “epicardial” 
spasm have a similar origin. Indeed, we have convincing experimental and clinical evidence that 
enhanced Rho-kinase activity in vascular smooth muscle cells - not in endothelial cells - plays a 
major pathogenic role14. In MVA, the presence of microvascular spasm helps explaining why a 
sizeable proportion of patients report predominantly angina at rest, or a combination of rest and 
effort-related angina. The importance of enhanced pain perception was initially proposed in 1988 
by Shapiro et al. and subsequently confirmed by other investigators. Using positron emission 
tomography to measure changes in regional cerebral blood flow as an index of neuronal activity, 
Rosen et al. provided evidence that altered central neural handling of afferent signals may 
contribute to the abnormal pain perception in patients with MVA. More recently, Valeriani et al. 
demonstrated abnormal cortical pain processing in patients with MVA. This was characterized by 
inadequate habituation to pain which might be the main cause of enhanced cardiac pain perception 
and also account for the symptomatic improvement observed in these patients using tricyclics and 
adenosine antagonists like theophylline15. It is worth noting that in MVA reduced CFR, hyper-
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reactivity to constrictor stimuli, and enhanced pain perception, may combine differently in different 
patients thus accounting for the disappointing results of standard angina treatments in many of these 
patients16.  
What about HFpEF? Which mechanisms in addition to endothelial dysfunction might orientate 
towards a phenotype characterized by dyspnoea rather than chest pain? It is conceivable that 
circulating factors might modulate the effects of CMD favouring the production of fibrosis and 
development of LVH. In this setting, fibrocytes, circulating monocyte-derived cells with tissue 
remodelling properties of fibroblasts, might play a modulating role17. Interestingly, in a murine 
model of cardiac remodelling in which fibrocytes are recruited to chronically injured myocardium, 
treatment of these animals with serum amyloid P decreased fibrocyte accumulation and fibrosis18. 
One of the main functions attributed to fibrocytes is extra-cellular matrix production, although it is 
possible that these cells may have other actions that are more typically associated with both 
macrophages and fibroblasts. Another modulating factor might be represented by atrial natriuretic 
peptide (ANP). Indeed, recent findings suggest that ANP signaling results in phosphorylation of 
Smad proteins, thus blocking their nuclear translocation and binding to TGF-Smad responsive 
elements in the promoter regions of extra-cellular matrix genes19. It is also worth considering that, 
as suggested by Pepine et al, cycles of ischemia-reperfusion might impair myocyte relaxation 
causing diastolic dysfunction and HFpEF20. The latter can, in turn, favor myocardial ischemia by 
increasing intramyocardial tension, an important determinant of myocardial oxygen consumption. 
This vicious circle may thus explain why dyspnea is a frequent symptom also in MVA whilst, on 
the other hand, angina is frequent in HFpEF. It may also explain why cTn is occasionally elevated 
in asymptomatic patients who will later go on to develop HFpEF, thus suggesting that subclinical 
ischemia can directly contribute to the pathogenesis of HFpEF21. Interestingly, Rho kinase 
inhibition, known to prevent epicardial and microvascular coronary spasm, improves diastolic 
function in hypertensive rats22. Attesting the gradual and progressive nature of these mechanisms, 
patients exhibiting HFpEF tend to be older than those presenting MVA. 
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A paradigm shift 
If the common soil hypothesis of MVA and HFpEF is correct, then a paradigm shift is needed, as 
CMD becomes a common diagnostic and therapeutic target for both of them. These two conditions 
have been identified and accepted by the scientific community only recently and rather reluctantly. 
The reason for this may be that these conditions do not exhibit the classic hallmark of ischemic 
heart disease (IHD) and of HF, namely epicardial stenoses and reduced EF, respectively. It is 
nevertheless increasingly acknowledged by the medical community that they represent a substantial 
public health burden because of their high prevalence and guarded prognosis, characterized not only 
by a higher mortality risk as compared to age and sex-matched asymptomatic subjects, but also by a 
high rate of hospital re-admissions.  
Thus, a first important challenge facing the scientific community is to devise strategies for the early 
diagnosis of CMD. The latter can be helped by the non-invasive assessment of CFR using 
transthoracic Doppler echocardiography, cardiac magnetic resonance or positron emission 
tomography. Furthermore, the demonstration of coronary microvascular spasm with intracoronary 
Ach, as well as measurements of coronary blood flow and the index of microcirculatory resistance 
during coronary angiography, may provide additional diagnostic information. A second challenge is 
the standardization of the diagnostic criteria for MVA and HFpEF. Efforts should be directed 
toward an accurate definition of these two conditions and this should be reflected in international 
guidelines as appropriate. A third challenge is the identification of new biomarkers for the diagnosis 
and risk stratification of MVA and HFpEF. Recent studies suggest that among patients with MVA, 
a lower CFR is associated with worse clinical outcomes, and suitable biomarkers are needed for 
prospective studies in larger cohorts of patients. Similarly, in patients with HFpEF, serum levels of 
certain biomarkers appear to correlate with diastolic load, although very limited evidence is 
available on the ability of such biomarkers to provide real diagnostic and prognostic information. 
Analogous considerations apply to recent techniques developed for the identification of interstitial 
myocardial fibrosis by cardiac magnetic resonance.  
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Therapeutic implications 
One of the future major challenges is the identification of effective evidence-based treatments for 
these conditions. Pharmacological agents currently available, that were developed to target large 
epicardial vessels and left ventricular dysfunction, are generally ineffective in controlling symptoms 
in patients with MVA and HFpEF and there is scarce evidence to ascertain whether they provide 
prognostic benefits in these patients.  
As the common soil of MVA and HFpEF is CMD, the latter should be the main therapeutic target 
for both conditions. Indeed, it is unlikely that one single treatment will be beneficial in all patients 
since the mechanisms of microvascular dysfunction are multiple. Consequently, it is important to 
develop therapeutic strategies that tackle both the functional and structural abnormalities underlying 
CMD. One crucial objective is to continue the fight against coronary risk factors both through the 
implementation of lifestyle changes and the use of drugs such as statins that have been shown to 
improve endothelial dysfunction. If the prevailing mechanism is smooth muscle cell hyper-
reactivity, then old and new vasodilators like Rho-kinase inhibitors might reduce the ischemic 
burden. In the subset in which the prevailing mechanism is vascular remodelling, ACE-inhibitors 
have been proved to be effective, particularly in hypertensive patients. In those cases where the 
prevailing mechanism is myocardial fibrosis, aldosterone antagonists and phosphodiesterase-
5inhibitors might be of help. Finally, in the patients in whom the prevailing mechanism is 
advanced coronary microvascular rarefaction cell therapy might be considered. 
In conclusion, we advocate action to develop appropriate diagnostic and therapeutic strategies for 
tackling these “new” diseases in the years to come.  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
8 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
9 
 
Figure legend 
The figure summarizes the common soil hypothesis for microvascular angina (MVA) and heart failure 
with preserved ejection fraction (HFpEF) including modulating factors, which can orientate at one 
extreme towards MVA and at the other extreme towards. Of note, ischemia per se can promote 
myocardial fibrosis. * Coronary micorvascular dysfunction is characterized by a variable combination 
of endothelial dysfunction, smooth muscle cell hyperreactivity, vascular remodeling, vascular 
rarefaction.  
Legend: HFpEF. ANP=atrial natriuretic peptides;. LVH=left ventricular hypertrophy; SMC=smooth 
muscle cells; TGF-=tissue growth factor-beta. 
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